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Gene Therapy Using Hepatocyte Growth Factor Expressing 
Adenovirus Improves Skin Flap Survival in a Rat Model
Hepatocyte growth factor (HGF) is a potent angiogenic factor that can stimulate the 
production of blood vessels in ischemic tissue. We investigated whether gene therapy using 
HGF-expressing adenovirus could enhance skin flap survival. Sprague-Dawley rats were 
randomly divided into three groups. Rats were subdermally injected with HGF-expressing 
adenovirus (HGF virus group), recombinant HGF (rhHGF group), or phosphate buffered 
saline (PBS group) 2 days before and immediately after 3 × 9 cm caudal flap elevation. The 
survival area of the skin flap, the ratio of blood flow, CD31-positive vessels and, VEGF 
expression were examined. Skin flap viability was significantly increased in the HGF virus 
group compared to the rhHGF and PBS groups (71.4% ± 5.9%, 63.8% ± 6.4%, and 
39.2% ± 13.0%, respectively) (P = 0.025). Furthermore, the blood flow ratio was 
significantly increased in the HGF virus group. In the HGF virus group, the number of 
CD31-positive vessels and vascular endothelial growth factor (VEGF) expression were 
significantly increased. Gene therapy using HGF-expressing adenovirus increase VEGF 
expression, the number of viable capillaries, and blood flow to the flap, thereby improving 
skin flap survival.
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INTRODUCTION
The creation of a skin flap is a simple and reproducible method 
for skin defect reconstruction. However, ischemic necrosis due 
to insufficient local blood supply is a serious complication of 
this procedure. Insufficient arterial blood supply and inadequate 
venous drainage are frequent occurrences and can result in skin 
flap death, especially in the distal portion where the blood flow 
is most likely to fail. Various surgical and non-surgical techniques 
have been devised to increase flap perfusion, thereby reducing 
the risk of ischemia. Among these, many reports have focused 
on increasing the local blood supply through inducing angio-
genesis by means of growth factors such as vascular endothelial 
growth factor (VEGF), fibroblast growth factor (FGF), or platelet 
derived growth factor (PDGF) (1-8).
 Hepatocyte growth factor (HGF) is a pleiotropic growth fac-
tor with an apparent molecular weight of 80 kDa that is capable 
of inducing cellular proliferation, migration, and invasiveness 
(9). One of the important activities of HGF is to stimulate angio-
genesis of various types of cells. HGF is a potent angiogenic fac-
tor and can act on endothelial cells directly or indirectly to in-
duce angiogenesis (10-12). Moreover, HGF stimulates the pro-
duction of functional vessels in the ischemic zone by promoting 
the migration of vascular smooth muscle cells as well as endo-
thelial proliferation (13). HGF has been reported to stimulate 
angiogenesis in rabbit, rat, and mouse ischemic hindlimb mod-
els of diabetes and high concentration lipoprotein (14-17). In 
addition, HGF has been reported to have more potent angio-
genic activity than VEGF and FGF in vitro (2). Because of its po-
tential angiogenic benefits, several studies have investigated 
whether HGF can increase skin flap perfusion (18). Although 
skin flap neovascularization can possibly be improved by HGF, 
its use in a clinical setting is hampered by this protein’s short 
half-life, poor bioavailability, and the consequent need for fre-
quent administration to sustain long-lasting effects. For HGF to 
be applied clinically, an efficient drug-delivery system or alter-
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native ways to realize the pharmacological effects of this growth 
factor need to be developed (19).
 Recent studies have shown that therapeutic angiogenesis in-
duced by gene therapy can result in a more sustained and effi-
cient therapeutic outcomes. Angiogenic growth factors have 
been evaluated in this context, and therapeutic angiogenesis 
using angiogenic growth factor therapy has been reported to 
have beneficial effects in human patients with critical limb isch-
emia and myocardial ischemia (2, 12, 20, 21). Of the various gene 
delivery systems developed for therapeutic angiogenesis, ade-
noviruses have been widely used because of their ability to trans-
fer relatively large genes. Therapeutic angiogenesis by gene de-
livery has been used to enhance the survival of skin flaps. 
 Inadequate perfusion, which is the most common cause of 
distal flap necrosis, could potentially be avoided by administer-
ing HGF to the skin flap. We therefore developed an HGF-ex-
pressing adenovirus and introduced this adenovirus into isch-
emic skin flaps to investigate the ability of subdermal HGF-ex-
pressing adenovirus gene therapy to augment blood perfusion 
and flap survival in a rat skin flap model.
MATERIALS AND METHODS
Animal preparation
The Institutional Animal Care and Use Committee of Yonsei 
University approved all animal protocols (2011-0143). Thirty 
male Sprague-Dawley rats weighing 300 to 350 g were used. Rats 
were maintained in a regulated airflow room in which tempera-
ture, humidity, and light were controlled. The rats were divided 
into three experimental groups. The HGF virus group was pre-
treated with a replication-incompetent adenovirus expressing 
HGF. The rhHGF group was pretreated with recombinant HGF 
(rhHGF). The PBS group was pretreated with phosphate buff-
ered saline (PBS). All three groups were pretreated by a subder-
mal injection distributed evenly across a total of eight injection 
points of the flap 2 days before flap elevation and immediately 
after flap elevation. 
Generation of HGF-expressing adenoviruses 
An HGF-expressing adenovirus (dE1-RGD/lacZ/HGF) was pro-
vided by Dr. Chae-Ok Yun (22) of Department of Bioengineer-
ing, College of Engineering, Hanyang University (Fig. 1). To de-
velop an adenovirus encoding the RGD peptide (9-amino acid 
sequence of CDCRGDCFC) between the HI-loop of the fiber 
knob, two complementary oligonucleotides encoding RGD (bold-
face and italicized) were first synthesized and annealed to form a 
DNA duplex. This DNA duplex was designed to contain a Bam-
HI overhang on the 5´ end and an MroI overhang on the 3´ end 
(underlined in the primer sequences below). The oligonucle-
otide sequences of the primers were 5´-gatccTGTGACTGCC-
GCGGAGACTGTTTCTGCt-3´ and 5´-ccggaACAATGACGGC-
GCCTCTGACAAAGACGg-3’. The annealed DNA duplex was 
then digested with NcoI and MfeI and cloned into pSK5543, gen-
erating a pSK [5543-RGD] adenovirus fiber shuttle vector. The 
pSK [5543-RGD] shuttle vector was then linearized by SacI and 
XmnI digestion, and the lacZ-expressing adenoviral vector pdE1/ 
lacZ was linearized by SpeI digestion for homologous recombi-
nation in Escherichia coli BJ5183, resulting in the pdE1-RGD/
lacZ adenoviral vector. To construct an adenovirus expressing 
lacZ and HGF at the E1 and E3 regions, respectively, pdE1-RGD/ 
lacZ was linearized by SpeI digestion and then co-transformed 
into Escherichia coli BJ5183 with the PvuI-digested pSP72-E3/
CMV-HGF shuttle vector for homologous recombination, yield-
ing the pdE1-RGD/lacZ/HGF adenoviral vector. All adenovi-
ruses were developed and multiplied in 293 cells. Viral particle 
numbers were calculated from measurements of absorbance at 
260 nm (A260), where 1 absorbency unit is equivalent to 1012 viral 
particles/mL. 
Experimental protocol
The rats were anesthetized with isoflurane (Aerane®; Ilsung 
Phar maceuticals, Seoul, Korea) and by intraperitoneal injection 
of a zolazepam-tiletamine mixture (30 mg/kg, Zoletil®; Virbac, 
Carros, France) and Xylazine (10 mg/kg, Rompun®; Bayer, Seoul, 
Korea). Body hair was removed from the entire dorsal area us-
ing depilatory cream. A 3 × 9 cm flap, including the panniculus 
carnosus muscle, was created from the dorsum of the prepared 
rats, and this flap was vertically elevated with its base on the 
caudal portion. To block new blood supply from the bed, a sili-
cone sheath (Bioplexus Corporation, Saticoy, CA, USA) was 
Fig. 1. Schematic representations of the adenoviral vectors. dE1-RGD/lacZ has the entire E1 region deleted and expresses the reporter gene lacZ (β-galactosidase protein) un-
der the control of the constitutive cytomegalovirus (CMV) promoter inserted into the E1 region. The replication-incompetent HGF-expressing adenovirus, dE1-RGD/lacZ/HGF, 
carries a HGF gene driven by the CMV promoter that was inserted into the E3 region. ΔE3 denotes the deletion of E3 gene. The RGD-incorporated adenovirus was generated by 
inserting RGD peptide between HI-loop of the fiber knob. ITR, inverted terminal repeat; Ψ, packaging signal; pA, polyA sequence; IX, protein IX; HGF, hepatocyte growth factor.
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placed on the flap bed and the flap was sutured with a 4-0 ny-
lon suture to its original location. To prevent the rats from biting 
the flaps on others after recovery from anesthesia, each rat was 
placed in a separate cage. Just before injecting the rats, 1 ×107 
plaque-forming units (PFU) of HGF-expressing adenovirus in a 
final volume of 800 µL, 500 ng of rhHGF (Abcam Inc, Cambri-
dge, MA, USA) in a final volume of 800 µL, or 800 µL of PBS were 
loaded into a 1-mL syringe with a 27-gauge needle. Injections 
were made into the subdermal layer of the entire area of the 
mapped skin flap (eight injection points) 2 days before flap ele-
vation and immediately after flap elevation.
Evaluation of skin flap survival rate
The elevated flaps were returned to their original position and 
flap survival was checked on postoperative days 3, 7, and 10. On 
days 3, 7, and 10, digital photographs were taken of the flap and 
these images were input into the Scion image program (NIH-
Scion Corporation, Frederick, MD, USA). Using this program, 
the len gth of the image was converted to the actual length and 
the surface area was calculated. The survival area was determin-
ed by subtracting the demarcated area of necrosis from the total 
surface area. Flap survival was calculated as the ratio of the via-
ble surface to the total surface area and expressed as a percentage.
In vivo measurement of microcirculation in the skin flap
To assess changes in blood flow in the skin flaps, we used the 
Periflux® System 5000 (Perimed AB, Jarfalla, Sweden). Serial 
measurements of skin vascularity were taken from four areas 
(proximal, mid-proximal, mid-distal, and distal portion) using 
laser Doppler flowmetry assessment of the initial status before 
injection of HGF expressing adenovirus, rhHGF, or PBS imme-
diately before flap elevation, immediately after flap elevation, 
and 3, 7, and 10 days after repositioning of the flap. Data were 
measured at the four flap points at 1-min intervals and the mean 
value was obtained. The ratio of blood flow was calculated as 
the blood flow immediately after flap elevation or that on post-
operative day 3, 7, and 10 divided by the initial blood flow be-
fore injection.
Immunostaining
Samples (1×1 cm) were taken along the longitudinal midline 5 
cm from the base of the skin flap on postoperative day 10 in the 
three experimental groups and fixed with 10% formaldehyde. 
Formaldehyde-fixed tissues were transferred into a paraffin-em-
bedded block, mounted on a slide, and stained with hematoxy-
lin and eosin for histological examination. 
 To detect HGF in tissues, paraffin sections were permeabiliz-
ed with 0.1% Triton X-100 solution. After washing three times, 
samples were blocked with 10% normal goat serum for 1 hr at 
37°C and incubated with goat anti-HGF antibody (R&D Systems, 
Inc.) at 4°C overnight and then with Alexa fluor 594 (Red)-label-
ed donkey anti-goat IgG (Invitrogen) at 37°C for 1 hr. Finally, the 
samples were incubated with 4,6-diamidino-2-phenylindole 
(DAPI; Sigma-Aldrich, St. Louis, MO, USA) for counterstaining 
and then observed using a BX51 fluorescent microscope (Olym-
pus).
 Tissue sections were pretreated with a 3% hydrogen peroxide 
solution for 10 min to block endogenous peroxidase and were 
then treated with protein block serum-free reagent (DAKO, Car-
pinteria, CA; X0909) for 30 min to prevent non-specific reactions. 
Sections were incubated at 4°C overnight with primary antibo-
dies (rabbit anti-vascular endothelial growth factor (VEGF); RB-
222-P; Laboratory Vision, Fremont, CA, antimouse platelet en-
dothelial cell adhesion molecule-1 (PECAM/CD31) polyclonal 
antibody; M20, Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
and then incubated at room temperature for 20 min with sec-
ondary antibodies from the DAKO Envision Kit (DAKO). 
 To calculate the amount of neovascularization, CD-31 posi-
tive vessels were counted and the number of vessels at each high 
power field (× 200) was recorded. The expression level of VEGF 
was semi-quantitatively analyzed using MetaMorph® image 
analysis software (Universal Image Corp). Results are expressed 
as the mean optical density (OD) of eight different digital images. 
Statistic analysis
Statistical analyses were performed using SAS statistical software 
(version 9.2, Cary, NC, USA). Each measurement is reported as 
the mean ± standard deviation. Differences between groups 
were assessed by one-way ANOVA adjusted by Bonferroni’s cor-
rection. P values of < 0.05 were considered significant.
RESULTS
Expression of HGF in the skin flaps
To evaluate if injection of HGF-expressing adenoviruses into 
the skin flap resulted in the expression of HGF in the skin flaps, 
we analyzed HGF expression by immunofluorescence staining 
on postoperative day 10 after local injection of HGF-expressing 
adenovirus (dE1-RGD/lacZ/HGF) or rhHGF. As expected, sig-
nificantly stronger immunoreactivity for HGF was found in the 
HGF-virus group than in the rhHGF group (Fig. 2). 
Effect of HGF-expressing adenoviruses on skin flap viability
In the PBS group, partial flap necrosis was observed and there 
was a significant, visible difference in the extent of necrosis among 
the three groups based on the digital photographs obtained on 
postoperative day 10 (Fig. 3A). Scion image program analysis 
on postoperative day 10 revealed that the skin flap survival area 
was significantly increased in the HGF virus group compared to 
the rhHGF and PBS groups (71.4% ± 5.9%, 63.8% ± 6.4%, and 
39.2% ± 13.0%, respectively) (P = 0.025) (Fig. 3B). 
 The administration of HGF in the form of a recombinant pro-
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Fig. 2. Immunofluorescence staining of HGF 10 days after flap elevation. Sections (3 
µm thick) of rat skin flap tissue (distal part) were stained with DAPI to label nuclei (A, 
D, G) and antibodies against HGF (B, E, H). Scale bars (50 µm) are indicated in all 
photomicrographs. Merged immunofluorescence images reveal that HGF is expressed 
in and around DAPI-stained cells (C, F, I).
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Fig. 3. Representative photographs of skin flaps survival. Partial flap necrosis on postoperative day 10 (A) and the extent of skin flap viability (B). Skin flap viability in the HGF vi-
rus group was significantly greater than that of the other groups on postoperative days 7 and 10. Values are means ± S.D. (n = 10). *P = 0.034; †P = 0.025.
tein or by gene delivery resulted in a higher rate of skin flap sur-
vival than PBS injection, and the highest rate of skin flap surviv-
al was observed in the adenovirus gene delivery group. 
Effect of HGF-expressing adenoviruses on the blood flow 
in the skin flap
Before flap elevation, the initial blood flow in the flap was not 
significantly different among the PBS group, rhHGF group, or 
HGF virus group (22.15 ± 8.95 perfusion units (PU), 24.46 ± 8.63 
PU, and 22.97 ± 6.19 PU, respectively). Blood flow as measured 
by laser Doppler flowmetry increased in both the rhHGF group 
and HGF virus group after injection, and the increase in blood 
flow was especially marked in the distal half of the skin flap. 
 In the mid-distal portion of the skin flap, the blood flow ratio 
was significantly increased on postoperative days 7 and 10 in 
the HGF virus group compared with the other two groups (0.56 
± 0.27, 0.71 ± 0.35, respectively, P = 0.028) (Fig. 4A). In the dis-
tal portion of the skin flap, there was a significant increase in 
the ratio of the blood flow in the HGF virus group (0.56 ± 0.50, 
0.35 ± 0.47, P = 0.017) on postoperative days 3 and 7 compared 
with the other two groups. Blood flow to the skin flap was main-
tained in the HGF virus group until postoperative day 10 in con-
trast to the other two groups (Fig. 4B). 
Effect of the HGF-expressing adenoviruses on capillary 
density in the skin flap
To calculate the amount of neovascularization, we performed 
CD31 immunohistochemical staining. More CD31-positive 
vessels were observed in the HGF virus group than the other 
two groups (Fig. 5A-C). A comparative analysis of the number 
of vessels at different high power fields (× 200) revealed no sig-
nificant difference in the number of CD31-positive vessels be-
tween the PBS group (3.8 ± 0.76) and rhHGF group (5.8 ± 0.80). 
However, the number of CD31-positive vessels was significantly 
higher in the HGF virus group (8.7 ± 2.91, P = 0.037) than the 
PBS and rhHGF groups (Fig. 5D).
Effect of the HGF-expressing adenoviruses on VEGF 
expression in the skin flap
Staining for VEGF immunoreactivity was higher in the HGF vi-
rus group than the other two groups (Fig. 6A-C). Semi-quanti-
tative analysis using MetaMorph® image analysis software (Uni-
versal Image Corp.) showed that VEGF expression was significant-
ly increased in the rhHGF group and HGF virus group (19,411.0 ±  
4,916.6 integrated OD and 29,439.4 ± 6,169.1 integrated OD, re-
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Fig. 4. Blood flow measurements in the skin flaps. In the mid-distal portion of skin flap, the ratio of the blood flow was significantly increased in the HGF virus group on postop-
erative days 7 and 10 compared with the other groups (A). In the distal portion of skin flap, there was significant increase in the ratio of blood flow in the HGF virus group on 
postoperative days 3 and 7 compared with the other groups (B). Values are means ± S.D. (n = 10). *P = 0.031; †P = 0.028; ‡P = 0.021; §P = 0.017.
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Fig. 5. Representative photomicrographs of CD31 immunohistochemistry. In distal part of flaps 10 days after flap elevation (PBS group (A), rhHGF group (B), HGF virus group (C), 
arrow: CD31-positive vessels, × 200) and the comparative analysis of the number of CD31-positive vessels (D). One-way ANOVA adjusted by Bonferroni’s correction revealed 
that the number of CD31-positive vessels was significantly higher in the HGF virus group than the other two groups. Values are means ± S.D. (n = 10). *P = 0.037.
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spectively) compared with the PBS group (9,844.4 ± 7,591.0 in-
tegrated OD). Furthermore, VEGF expression was significantly 
higher in the HGF virus group than the rhHGF group (P = 0.029) 
(Fig. 6D).
DISCUSSION
Distal skin ischemic necrosis is a common complication of skin 
flap surgery. Among the methods that have been devised to in-
crease skin flap perfusion to reduce the risk of skin ischemic ne-
crosis, those methods that increase the local blood supply through 
growth factor-stimulated angiogenesis induction using growth 
factors such as VEGF, FGF, and platelet-derived growth factor 
(PDGF) have reported promising results (1-8). To induce angio-
genesis by means of growth factors, recombinant proteins or 
genes encoding the growth factor of interest need to be admin-
istered to the site of interest. Recombinant protein therapy is 
the most practical means to administer angiogenic agents. How-
ever, a very high dose of protein may be necessary to achi eve ad-
equate uptake, which often results in an unacceptably high ad-
verse event rate. Moreover, a single administration of growth 
factor is unlikely to result in sufficient growth factor levels for a 
beneficial result to be observed. In contrast, administration of 
the gene coding for the protein of interest can potentially result 
in sustained local protein secretion with minimal adverse ef-
fects. Furthermore, the efficacy of gene uptake has been shown 
to be enhanced in ischemic tissue (12). Therefore, we performed 
gene therapy to improve ischemic skin flap survival.
 Of the various gene carriers that have been investigated, ade-
noviruses are widely used because of their ability to transfer rel-
atively large genes to dividing or non-dividing cells (23, 24). Se-
veral experimental studies have reported that administration of 
VEGF-expressing adenoviruses can result in therapeutic angio-
genesis (7, 21, 25). Huang et al. (7) reported a correlation be-
tween flap survival and injection of an adenovirus expressing 
VEGF-165. Recently Zheng et al. (25, 26) reported even greater 
200 µm 200 µm
200 µm D
Th
e 
ex
pr
es
si
on
 le
ve
l o
f V
EG
F 
(O
D)
 PBS group rhHGF group HGF virus group
40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000
0
*
Fig. 6. Representative photomicrographs of VEGF immunohistochemistry. In distal part of flaps 10 days after flap elevation (PBS group (A), rhHGF group (B), HGF virus group (C), 
× 200) and semi-quantitative analysis using MetaMorph® image analysis software (D). One-way ANOVA adjusted by Bonferroni’s correction revealed that VEGF immunoreactivity 
was significantly higher in the HGF virus group than the other two groups. Values are means ± S.D. (n = 10). *P = 0.029.
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flap survival due to increased VEGF expression by incorporat-
ing the VEGF gene into vectors using genetic transformation of 
mesenchymal stem cells. Our research group recently reported 
increase of flap survival with relaxin expressing adenovirus (27). 
 In this time, we generated an HGF-expressing, replication-
incompetent adenovirus (dE1-RGD/lacZ/HGF) and subder-
mally injected this virus into rat skin flaps. The function of RGD 
sequence in HGF-expressing adenovirus is to promote gene 
delivery into cells (27). These replication-incompetent adeno-
viruses have limited anti-cancer gene therapy effects in that 
their anti-cancer effects are restricted to adjacent infected cells. 
However, they are effective at delivering genes to ischemic skin 
flaps to augment blood flow, as the results of this study show. 
 HGF is a pleiotropic growth factor with a variety of biological 
effects. HGF has been shown to function as an angiogenic fac-
tor in vitro, and induction of angiogenesis by HGF supplemen-
tation has been shown to improve local hypoxia (9, 16, 28, 29). 
In contrast to other angiogenic factors, HGF has anti-inflamma-
tory and antithrombotic effects (30-32). HGF is therefore ideal 
for therapeutic angiogenesis, even under hypoxic conditions 
such as those that characterize ischemic skin flaps.
 However, pharmacokinetic analyses have revealed that the 
half-life of HGF is short - approximately 4 min. Because the ef-
fectiveness of HGF protein therapy might be limited by its short 
half-life, HGF gene therapy is key to the steady, perioperative 
release of HGF. Based on our results, delivery of HGF through 
an adenovirus rather than directly appears to be a feasible and 
effective treatment option. In our experimental studies, the time 
frame chosen for injection was 2 days before flap elevation and 
immediately after flap elevation; this time frame and the dose 
of HGF were determined on the basis of pilot experiments (data 
was not shown) and a review of the literature (2, 21). And we 
confirmed that HGF was expressed from transferred adenovi-
rus by immunofluorescence staining on 10 days after flap ele-
vation. Moreover, the amount of HGF was greater in adenovirus 
group than in rhHGF group (Fig. 2). We also performed the same 
experiment with control virus without HGF gene. But, we didn’t 
show the result in this report because it was almost same to the 
result of the PBS group.
 In the present study, flap survival was significantly increased 
in the HGF virus group compared to the other groups on post-
operative days 7 and 10. Although gene transfer of other angio-
genic factor such as VEGF, PDGF, and angiopoietin-1 has been 
shown to improve skin flap survival (33-35), transfer of the HGF 
gene into the skin flap via an HGF-expressing adenovirus has 
not yet been investigated. And we compared the effect of rhH-
GF and HGF-expressing adenovirus in same study and condi-
tion. Thus, we demonstrated that adenovirus-mediated HGF 
gene therapy in the skin flap increases skin flap viability. 
 In contrast to the rhHGF group, the HGF virus group showed 
a significant increase in the numbers of CD31-positive vessels 
and the expression level of VEGF in skin flap samples taken on 
postoperative day 10. Furthermore, immunoreactivity for HGF 
was stronger in the HGF virus group than the rhHGF group. This 
indicates that the transferred HGF gene had a significant effect 
on neovascularization. The significant increase in numbers of 
CD31-positive vessels also indicates that the adenovirus-express-
ed HGF acted directly on endothelial cells to induce angiogen-
esis and that it did so more effectively than rhHGF. The increase 
in intensity of VEGF staining suggests that HGF gene transfer 
also had a stronger indirect angiogenic effect through the up-
regulation of VEGF than rhHGF (13). The significant difference 
in numbers of CD31-positive vessels and the increased expres-
sion level of VEGF on postoperative day 10 in the HGF-express-
ing adenovirus group suggests that HGF was produced in a sus-
tained way and thereby promoted angiogenesis and induced 
the production of VEGF until postoperative day 10 in contrast 
to rhHGF, which had a transient effect. 
 We observed a significant increase in the ratio of blood flow 
in the HGF virus group in the mid-distal portion and distal por-
tion of the skin flap until postoperative day 7. Serial measure-
ments of blood perfusion demonstrated that blood flow to the 
mid-distal portion and distal portion was maintained up to post-
operative day 10; in contrast, no blood flow to the skin flap was 
observed in the other two groups. The maximum time for skin 
ischemic tolerance in rat, rabbit, and pig skin flaps ranges from 
6-13 hr, but it takes longer than this to establish HGF-induced 
angiogenesis (3). Therefore, the time required for HGF-induced 
angiogenesis is longer than the critical ischemic time of the skin 
flap. Overexpression of HGF leads to local blood flow not only 
by angiogenesis, but also vascular relaxation induced by impro-
vement in endothelial function (36, 37). HGF has been shown 
to up-regulate VEGF, which is a potent vasodilator that medi-
ates the release of nitric oxide (3, 38). It is therefore likely that 
the overexpression of HGF by HGF-expressing adenoviruses 
improved endothelial function and stimulated the production 
of VEGF followed by vasodilatation within the time frame for 
skin ischemic tolerance. As a result, the mid-distal and distal 
portions of the skin flap in the HGF virus group were protected 
against irreversible ischemic changes and blood flow was main-
tained. Despite this role, the potential therapeutic use of HGF-
expressing adenovirus possesses limitations for safe and effec-
tive gene therapy because of acute inflammatory responses and 
innate immune response. Exhaustive research efforts have prom-
pted the development of novel strategies to overcome these 
limitations (39). Therefore, we think that further refinement 
studies will be needed for more efficient and safe gene transfer 
in patients.
 We generated and introduced an HGF-expressing adenovi-
rus (dE1-RGD/lacZ/HGF) into a rat skin flap model. Adminis-
tration of HGF-expressing adenoviruses into ischemic skin flaps 
increase skin flap viability, blood flow to the flap, the number of 
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viable capillaries, and VEGF expression, thereby improving the 
skin flap survival rate.
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